Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Window-of-opportunity Study of Pelareorep in Early Breast Cancer
NCT04102618Phase 1Terminated
- Sponsor
- Oncolytics Biotech Inc.
- Start
- Mar 2019
- Primary completion
- Apr 2022
- Modality
- Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pelareorep in breast cancer (6 cohorts), sponsored by Oncolytics Biotech Inc. Primary endpoint: CelTIL score at Day 21. Started Mar 2019; status: terminated.
02
Drugs
pelareorep
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04102618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102618.